CN114052261A

CN114052261A - Application of phospholipid in reducing friability of kelp dietary fiber chips and improving taste

Info

Publication number: CN114052261A
Application number: CN202111337019.1A
Authority: CN
Inventors: 郝守祝; 咸大鹏
Original assignee: Nanjing Century Bokang Pharmaceutical Technology Co ltd
Current assignee: Nanjing Century Bokang Pharmaceutical Technology Co ltd
Priority date: 2016-11-21
Filing date: 2016-11-21
Publication date: 2022-02-18
Also published as: CN106723087A

Abstract

The invention relates to a kelp dietary fiber tablet and a preparation method thereof, belonging to the field of health-care food and processing thereof. The active ingredients of the disclosed tablet containing the kelp dietary fiber comprise kelp dietary fiber, oligosaccharide and phospholipid, and the auxiliary material is a pharmaceutically acceptable auxiliary material for preparing the tablet, and at least comprises a lubricant. The kelp dietary fiber, the oligosaccharide and the phospholipid are combined together, and the three components have synergistic effect, so that the kelp dietary fiber, the oligosaccharide and the phospholipid have the effects of losing weight, treating constipation, treating diabetes, reducing hyperlipidemia, resisting aging, resisting tumors, removing heavy metals in vivo and the like, and particularly have very obvious effect on treating constipation.

Description

Application of phospholipid in reducing friability of kelp dietary fiber chips and improving taste

The application is named as follows: a tablet containing kelp dietary fiber and a preparation method thereof, the application number is as follows: 201611021537.1.

Technical Field

The invention relates to a kelp dietary fiber tablet and a preparation method thereof, belonging to the field of health-care food and processing thereof.

Background

With the development of socio-economy, the pace of life is accelerated, the working pressure is increased, and the overloaded life and working pressure for a long time results in that 70% of people in the world suffer from gastrointestinal diseases to different degrees. Constipation is the most common functional gastrointestinal tract disease in clinic and is mainly manifested by the reduction of defecation frequency, the reduction of stool quantity, dry and hard stool, the waste of defecation and the like. Constipation is not only a common health problem but also a causative factor in many fatal diseases such as acute cardiovascular and cerebrovascular diseases, dementia, and colon cancer, with prevalence rates as high as 27%. In recent years, along with the change of dietary structure and the influence of psychopsychological and social factors, the incidence rate of constipation is increasing, the life quality of people is seriously influenced, and factors such as complex etiology, difficult treatment, easy relapse, long treatment period, great side effect and the like are common diseases which puzzle the society.

Obesity is a chronic metabolic disease caused by various factors and is characterized by abnormal increase in the percentage of body fat to body weight and excessive deposition of fat in some parts due to increase in the volume and number of fat cells in the body. In the last two decades, with the rapid development of economy in China, the living standard of people is continuously improved, the modern dietary structure of life is changed, physical activity is gradually reduced, and the obesity phenomenon is more and more common. Obesity is known to have obvious correlation with diseases such as diabetes, cardiovascular diseases, certain tumors, sleep-respiratory disorder and the like, and obesity-concurrent diseases comprise: coronary heart disease, hypertension and stroke, certain cancers, non-insulin dependent diabetes mellitus, gallbladder diseases, osteoarthritis and gout, dyslipidemia and lung diseases including sleep apnea, obesity is a main risk factor for various cancers such as hypertension, diabetes, dyslipidemia, coronary heart disease, myocardial infarction, stroke, breast cancer and the like, and is identified as the fifth major risk factor affecting health by the world health organization.

Hypertension (hypertension) is a clinical syndrome characterized by an increase in systemic arterial blood pressure (systolic pressure and/or diastolic pressure) (systolic pressure not less than 140 mm hg, diastolic pressure not less than 90 mm hg), which may be accompanied by functional or organic damage to organs such as heart, brain, kidney, etc. Hypertension is the most common chronic disease and also the most major risk factor for cardiovascular and cerebrovascular diseases. An initial estimate of 2.66 hundred million hypertensive patients in 2012 was made in China. Both domestic and foreign studies prove that the blood pressure level of hypertension patients can be reduced by 40-50% of stroke and 15-30% of myocardial infarction risk. Therefore, controlling hypertension is an entry point for cardiovascular disease control.

Diabetes is a metabolic disease characterized by chronic elevated blood glucose levels, which is caused by defects in insulin secretion and/or action, and with the progress of the disease, causes damage to many systems of the human body, and also greatly reduces the living standard of the patient. According to WHO statistics, the number of diabetic patients is more than 1.7 hundred million globally in 2000, and more than 3.6 hundred million is predicted in 2030. The prevalence rate of diabetes in China is on a rapid increase trend. Recent epidemiological investigations have shown that the prevalence of diabetes in chinese adults in 2010 has reached 11.6%. The increase of the incidence of diabetes increases the burden of individuals, families and society. Research shows that the prevalence rate of diabetes in cities, towns and affluent rural people over 20 years old in China is 9.7%, and 15.5% of people suffer from impaired blood glucose regulation. Diabetic microvascular and macrovascular complications cause disability, death risks and huge economic burdens, and diabetes has become a major problem affecting the health of residents.

Hyperlipidemia, manifested as dyslipidemia or dyslipidemia, refers to a condition in which the concentration of serum lipids in the body is outside the normal range, including elevated serum Total Cholesterol (TC) levels. Serum Triglyceride (TG) level is increased, and serum high density lipoprotein cholesterol (HDL-C) level is reduced, which is one of the main risk factors of cardiovascular and cerebrovascular diseases. Hyperlipidemia is common in middle-aged and elderly people, but with the change of dietary structure and the increase of drinking capacity, the prevalence rate of young people also increases year by year. A large number of epidemiological surveys and studies indicate that hyperlipidemia is a risk factor for Atherosclerosis (AS), coronary heart disease, diabetes and other diseases.

In addition to traditional pharmacotherapeutic regimens, the nutrition industry has recently attempted to provide several functional, health foods and nutraceuticals to ameliorate the above-mentioned problems of people due to dietary habits, in response to the various health and sub-health problems described above. Among these, dietary fiber is one direction that is currently attracting much attention and spreading. Dietary Fiber (DF) is a complex mixture of polymers, a generic term for indigestible polysaccharides carbohydrates and lignin. Researches in the 60 s of the 20 th century and later discover that eating high-fiber food is beneficial to reducing the incidence of diseases such as diabetes, hyperlipidemia and the like. This has aroused interest in dietary fibre and has led to systematic studies. Research in nutrition and related sciences has found that dietary fiber has a very important physiological role and is recognized by the nutritional community as a seventh group of nutrients and the traditional six groups of nutrients-protein, fat, carbohydrate, vitamins, minerals, juxtaposed to water. The dietary fiber is not decomposed and absorbed by digestive enzymes of human bodies, but is a nutrient which maintains the health of human bodies and cannot be replaced by other substances. A great deal of facts show that the dietary fiber can keep normal peristalsis of human intestinal tracts, is related to digestion and absorption of protein, fat, available carbohydrate, vitamins and mineral substances, and can make food in the intestinal tracts swell and soften and promote the peristalsis of the intestinal tracts by supplementing the dietary fiber in a proper amount, so that the defecation speed is increased, constipation is prevented, and the risk of intestinal cancer is reduced. In addition, the dietary fiber has effects of relieving obesity, cardiovascular diseases, diabetes, heart diseases, and autoimmune system disorder.

The dietary fiber is widely existed in cereals, beans, fruits, vegetables and marine algae, the components of the dietary fiber extracted from different raw materials have great difference, and the physical and chemical properties and physiological functions of the dietary fiber have very obvious difference. Among them, kelp has attracted much attention in recent years from the nutritional society as a marine crop rich in various nutrients.

CN 101317666A discloses a high-efficiency composite dietary fiber, which is prepared from insoluble dietary fiber, water-soluble dietary fiber, vitamin C, lactobacillus powder and the like into capsules and granules, however, in the scheme, the dosage of the dietary fiber is too high, and the dietary fiber is lack of the complex ingredients, so that the high-efficiency composite dietary fiber has poor taste and flavor, and is not easy to be accepted by consumers. CN102077939 discloses a special dietary food for sea, which is prepared from food-derived marine oligopeptide as main raw material, marine bioactive polysaccharide, and Sargassum powder, nutritional amino acids, oligosaccharide, nutrients, vitamins and minerals by mixing. The product has complex composition, high production and raw material cost and difficult popularization to the market. CN103202469 discloses a microcapsule, which uses egg yolk lecithin as core material, sodium alginate and chitosan as wall material. The microcapsule has low encapsulation capacity to egg yolk lecithin and sodium alginate, and cannot fully exert the activity of the egg yolk lecithin and the sodium alginate.

Disclosure of Invention

In the present invention, terms referred to are the following concepts:

the tablet referred to in the present invention refers to a round or irregular shaped tablet solid preparation made of raw material drugs or with appropriate excipients, as known to those skilled in the art, and its common dosage forms include ordinary tablets, buccal tablets, sublingual tablets, buccal patches, chewable tablets, dispersible tablets, soluble tablets, effervescent tablets, sustained release tablets, controlled release tablets, enteric coated tablets, orally disintegrating tablets, etc.

The active ingredients in the invention are ingredients which are helpful for improving the functions of human bodies and overcoming the physiological disorders of the human bodies in the process of taking and absorbing the active ingredients by human bodies.

The auxiliary materials in the invention refer to excipients and additives used in the preparation process of medicines, health products, foods and the like, and the pharmaceutically acceptable refers to the fact that the auxiliary materials are proved to be relatively nontoxic and harmless to patients in the existing pharmaceutical application.

The invention discloses a tablet containing kelp dietary fiber, which comprises active ingredients of kelp dietary fiber, oligosaccharide and phospholipid, and auxiliary materials which are pharmaceutically acceptable and used for preparing tablets, wherein the auxiliary materials at least comprise a lubricant.

For convenience of administration and easy absorption, the dosage form of the above-mentioned tablets is preferably chewable tablets.

The applicant researches the composition dosage of the components through a plurality of experiments, preferably, 30 to 70 parts by weight of kelp dietary fiber, 10 to 40 parts by weight of oligosaccharide, 10 to 40 parts by weight of phospholipid and 0.2 to 6 parts by weight of lubricant in auxiliary materials.

In the above, the phrase that the auxiliary material at least contains a lubricant means that at least the auxiliary material of the lubricant is used in the tablet of the present invention. In addition, other types of excipients may be used depending on the dosage form, manufacturing, etc.

Correspondingly, the invention also provides a preparation method of the tablet, which comprises the following steps:

a) sieving the kelp dietary fiber with a 60-200 mesh sieve for later use;

b) weighing kelp dietary fiber, oligosaccharide and phospholipid, and uniformly mixing;

c) adding water to prepare soft materials, granulating by using a 14-30-mesh sieve, and putting into an oven at the temperature of 40-70 ℃ for blast drying for 0.5-4 h;

d) taking out, granulating with 14-30 mesh sieve, adding lubricant, and mixing;

e) and tabletting according to the specified tablet.

When the adjuvants used also comprise other types of adjuvants than lubricants, other adjuvants than lubricants are added in step b).

In the steps, a) the kelp dietary fiber is sieved by a sieve of 60-200 meshes, so that the product has good appearance and excellent properties, theoretically, the smaller the particle size is, the better the product is, but the smaller the particle size is, the larger the crushing energy consumption is, and the flowability is poor, therefore, the kelp dietary fiber of 60-200 meshes can meet the requirements of all properties. Among them, 100 mesh is preferable.

In the above steps, the granulation in the step c) can meet the requirement by using a 14-30 mesh sieve, wherein the granulation is preferably finished by using a 20 mesh sieve, and the drying temperature is selected from 40-70 ℃. Wherein the temperature is lower than 40 ℃, the drying efficiency is too low, the stability of the material is reduced when the temperature is higher than 70 ℃, and the temperature is preferably 45-55 ℃. The drying time is determined according to the drying temperature, the thickness of the material and other factors, and the drying time is between 0.5h and 4 h. Wherein, if the drying temperature is high and the material is thin, the drying time is short, and if the drying temperature is low and the material is thick, the drying time is long. The person skilled in the art will be able to determine the corresponding drying time depending on the temperature of drying.

In the above step, the 14-30 mesh sieve is selected for the finishing in step d), and generally, the mesh size is selected according to the mesh size selected for the granulation, and the mesh size is selected for the finishing.

In the step e), tabletting is carried out, the weight to be tabletted is calculated according to the measurement result of the designed tablet weight or the designed tablet weight and the particle content, and tabletting is carried out, wherein the tablet weight is controlled to accord with the pharmacopoeia regulation. All can be realized by a person skilled in the art.

For tablet-based derived dosage forms, such as film-coated or sugar-coated tablets, the step of film-coating or sugar-coating is also included. Wherein, the coating can be coated with gastric-soluble film coat or enteric-soluble film coat or sugar coat, and the materials and the process for coating have no special requirements, and can be realized by the technicians in the field.

Finally, the invention also provides the application of the kelp dietary fiber tablet, including but not limited to the application in preparing weight-losing medicines or health-care foods, the application in preparing medicines or health-care products for treating constipation, the application in preparing medicines or health-care products for treating diabetes, the application in preparing medicines or health-care products for treating hyperlipidemia and the application in preparing antihypertensive medicines or health-care products.

In the following description, in order to better explain the contents of the present invention, the applicant has elaborated on the components used in the technical solution of the present invention in order to better understand the present invention for the person skilled in the art.

In the kelp dietary fiber tablet of the present invention, the kelp dietary fiber is selected from: one or mixture of water soluble kelp dietary fiber and water insoluble kelp dietary fiber, preferably mixture of water soluble kelp dietary fiber and water insoluble kelp dietary fiber.

Wherein the water-soluble kelp dietary fiber is preferably sodium alginate.

In the tablet of the present invention, the oligosaccharide is one or more selected from the group consisting of xylooligosaccharide, isomaltooligosaccharide, fructooligosaccharide, galactooligosaccharide, soybean oligosaccharide, cottonseed oligosaccharide, inulin oligosaccharide, gentiooligosaccharide, palatinose oligosaccharide, aspergillus oligosaccharide, coupling oligosaccharide, arabinose oligosaccharide, lactulose, trehalose, stachyose, chitosan, and chitosan, preferably xylooligosaccharide.

In the tablet of the invention, the phospholipid is selected from one or a mixture of plant-derived phospholipids and animal-derived phospholipids, or single-component phospholipids obtained by separating and purifying the plant-derived phospholipids and the animal-derived phospholipids; the plant-derived phospholipid is obtained by extracting and refining plant oil materials such as soybean, cottonseed, rapeseed, peanut kernel, sunflower seed and the like or processing byproducts thereof serving as main raw materials, and preferably meets the phospholipid of national standard GB28401-2012 issued by the Ministry of health of the people's republic of China; wherein the animal-derived phospholipid is prepared by extracting and refining animal egg, brain, liver, kidney, heart, lung, etc.; wherein the separated and purified single-component phospholipid is selected from one of lecithin, cephalin, inositol phospholipid, serine phospholipid, phosphatidyl glycerol, diphosphatidyl glycerol, plasmalogen, lysophospholipid, sphingomyelin and sphingoglycolipid.

Wherein the plant-derived phospholipid is soybean phospholipid, and the animal-derived phospholipid is egg yolk lecithin.

In the tablet of the present invention, the lubricant is selected from one or more of magnesium stearate, calcium stearate, zinc stearate, sodium stearate, lithium stearate, potassium stearate, stearic acid, palmitic acid, magnesium trisilicate, synthetic wax, hard paraffin, hydrogenated vegetable oil, cetyl alcohol, glyceryl monostearate, silicified microcrystalline cellulose, silicon dioxide, talc, sodium benzoate, sodium oleate, sodium lauryl sulfate, magnesium lauryl sulfate, adipic acid, fumaric acid, polyethylene glycol 1000, polyethylene glycol 4000, polyethylene glycol 6000, sodium chloride, leucine, preferably magnesium stearate, silicon dioxide or a mixture of both.

Those skilled in the art will readily appreciate that various other desirable adjuvants may be optionally added for convenience of consumption.

In order to improve the mouthfeel of the tablet, the auxiliary materials of the tablet also comprise a sweetening agent, and the sweetening agent is selected from the following components: aspartame, saccharin sodium, sucralose, cyclamate, alitame, neotame (N- [ N- (3, 3-dimethylbutyl) -L-alpha-aspartyl ] -L-phenylalanine 1-methyl ester), acesulfame potassium, stevioside, mannitol, xylitol, sorbitol, fructose, glucose, maltose and sucrose. Among the above sweeteners, those that increase sweetness without increasing calories, i.e., that have sweetness without providing energy, and that do not alter blood glucose levels, are preferred in view of diabetic and bariatric applications, and include, but are not limited to, one or more of aspartame, saccharin sodium, sucralose, sodium cyclamate (sodium cyclamate), alitame, neotame (N- [ N- (3, 3-dimethylbutyl) -L- α -aspartyl ] -L-phenylalanine 1-methyl ester), acesulfame potassium, stevia, mannitol, xylitol, sorbitol, maltose.

When the auxiliary materials are selected from lubricant and sweetener, the tablet comprises 30-70 parts by weight of kelp dietary fiber, 10-40 parts by weight of oligosaccharide, 10-40 parts by weight of phospholipid, 0.2-6 parts by weight of lubricant and 0.1-20 parts by weight of sweetener.

In order to make the tablet have better compressibility and facilitate the regulation of tablet weight, the auxiliary materials of the tablet also comprise a filler, wherein the filler is selected from one or more of mannitol, lactose, microcrystalline cellulose, starch, pregelatinized starch, soluble starch, dextrin, sorbitol, maltitol and isomaltooligosaccharide, and preferably the mannitol.

When the auxiliary materials are selected from a lubricant and a filler, the composition of the tablet comprises, by mass, 30-70 parts of kelp dietary fiber, 10-40 parts of oligosaccharide, 10-40 parts of phospholipid, 0.2-6 parts of a lubricant and 1-49 parts of a filler.

In order to improve the taste of the tablet, improve the compressibility and facilitate the regulation of the weight of the tablet, on the basis of the above, the auxiliary materials used by the tablet simultaneously comprise 30 to 70 parts by weight of kelp dietary fiber, 10 to 40 parts by weight of oligosaccharide, 10 to 40 parts by weight of phospholipid, 0.2 to 6 parts by weight of lubricant, 0.1 to 20 parts by weight of sweetener and 1 to 49 parts by weight of filler. In the composition, the wetting agent preferably adopts magnesium stearate and silicon dioxide, wherein the magnesium stearate is 0.1-3, and the silicon dioxide is 0.1-3.

On the basis of the above, in order to meet the needs of the market, improve the appearance, increase the moisture resistance, increase the stability and the like, the tablet of the present invention may be further coated with a film coating to prepare a film-coated tablet or coated with a sugar coating to prepare a sugar-coated tablet (film-coated tablet refers to a tablet coated with a film of a high-molecular material; sugar-coated tablet refers to a tablet coated mainly with sugar as a coating material).

In a preferred implementation of the invention, the provided kelp dietary fiber tablet is a chewable tablet so as to provide the most convenient eating way for consumers, promote the dissolution and absorption of the medicine in vivo, be convenient for the old, children and patients with swallowing difficulty and poor gastrointestinal function, and reduce the burden of the medicine on the gastrointestinal tract. In the chewable tablet, the kelp dietary fiber is preferably a mixture of water-soluble kelp dietary fiber and water-insoluble kelp dietary fiber, the oligosaccharide is preferably xylooligosaccharide, the phospholipid is preferably soybean phospholipid, and the lubricant is preferably magnesium stearate and silicon dioxide.

Compared with the conventional chewable tablet, the chewable tablet has the fragrance of phospholipid due to the addition of the phospholipid, and the mouthfeel is greatly improved due to the addition of the phospholipid. Meanwhile, the phospholipid can promote the blood circulation of intestines and stomach and the peristalsis of intestines and stomach, and is helpful for preventing and improving constipation. In addition, the use of the phospholipid can not only reduce the hardness of the product, but also reduce the friability of the product after the hardness is reduced without increasing. The product has better friability.

In a further implementation of the chewable tablet, a sweetening agent is also added, and the sweetening agent is preferably aspartame.

Wherein, the chewable tablet comprises 30 to 70 parts by weight of kelp dietary fiber, 10 to 40 parts by weight of xylo-oligosaccharide, 10 to 40 parts by weight of phospholipid, 0.1 to 3 parts by weight of silicon dioxide, 0.1 to 3 parts by weight of magnesium stearate and 0.1 to 2 parts by weight of aspartame. Preferably, kelp dietary fiber 49, xylo-oligosaccharide 24.5, soybean phospholipid 24.5, silicon dioxide 0.5, magnesium stearate 1 and aspartame 0.5.

The kelp dietary fiber used in the product of the invention is a mixed dietary fiber prepared by taking high-quality kelp as a raw material, performing alcohol extraction and decoloration, removing fishy smell, acid extraction and calcium and magnesium removal, removing small molecular substances, alkalizing to increase water-soluble kelp dietary fiber, and dehydrating and drying. The kelp dietary fiber consists of water-soluble dietary fiber and water-insoluble dietary fiber, wherein the water-soluble dietary fiber is mainly sodium alginate, and the water-insoluble dietary fiber is mainly a constituent component of kelp cell walls and is a fiber different from terrestrial plant cell walls. The kelp dietary fiber contains 40% of water-insoluble dietary fiber and 30% of water-soluble dietary fiber, so that the kelp dietary fiber has strong water holding capacity and expansibility after being subjected to superfine grinding and uniform mixing, is much higher than the wheat dietary fiber of terrestrial plants, can increase the volume and speed of defecation of a human body, and relieves the pressure in the rectum and the urinary system. Besides the water-holding expansion of the conventional dietary fiber, the kelp dietary fiber has excellent performances of adsorbing heavy metals, adsorbing fat, relieving sugar digestion and absorption and the like.

The product of the invention uses oligosaccharide which is a polymer condensed by a few monosaccharides (2-10), and has the following characteristics: improving micro-ecological environment in human body, facilitating proliferation of Bacillus bifidus and other beneficial bacteria, producing organic acid through metabolism to reduce intestinal pH, inhibiting growth of Salmonella and putrefying bacteria in intestine, regulating gastrointestinal function, inhibiting intestinal putrefying substance, changing stool character, preventing and treating constipation, increasing vitamin synthesis, and improving immunity; the oligosaccharide is similar to water soluble plant fiber, and has effects in improving blood lipid metabolism, and reducing cholesterol and triglyceride content in blood; the food is not dependent on insulin, does not increase blood sugar, and is suitable for hyperglycemia people and diabetes patients; is difficult to be hydrolyzed by salivary enzyme and small intestine digestive enzyme, has low calorific value, is rarely converted into fat, and has no side effect on obesity patients; it is not formed into matrix by dental caries bacteria, and has no thallus coagulation effect, and can be used for preventing dental caries; inhibit the formation of intestinal putrefaction products, and inhibit beta-glucuronidase and azoreductase related to carcinogenic substances.

The xylooligosaccharide preferably used is a linear chain or branched chain low-polymerization-degree functional sugar formed by connecting 2-7D-xylose molecules by beta-1, 4-glycosidic bonds, and part of the xylooligosaccharide also contains arabinouronic acid and glucuronic acid side chains, wherein xylobiose and xylotriose are taken as main components, and the xylooligosaccharide is a functional oligosaccharide prebiotic. The sweetness of the xylo-oligosaccharide is pure and similar to that of cane sugar, but the sweetness of the xylo-oligosaccharide is lower than that of cane sugar and glucose, and is about 40 percent of that of the cane sugar. The xylo-oligosaccharide has good stability to pH and heat, is not decomposed basically even heated under an acidic condition, and because the gastrointestinal tract of a body is lack of an enzyme system for hydrolyzing the xylo-oligosaccharide, the xylo-oligosaccharide can smoothly pass through the stomach and the small intestine and is not degraded and utilized, but directly enters the large intestine and is utilized by beneficial bacteria such as bifidobacterium, lactobacillus and the like, and the utilization rate of the harmful bacteria is extremely low or unavailable, so that the beneficial bacteria can grow and propagate in a large amount. The xylo-oligosaccharide is extracted from corncob and is a prebiotic with the strongest proliferation effect on bifidobacteria in functional oligosaccharide. Can effectively regulate intestinal microecological balance, inhibit growth and reproduction of other harmful bacteria, and is difficult to be decomposed by human digestive enzyme system. It is a dietary fiber, can increase water holding capacity and stool quantity, and can ferment bacteria in large intestine to generate organic acids such as acetic acid, propionic acid and lactic acid, so as to acidify intestinal tract, stimulate intestinal tract peristalsis, and relax bowel.

The phospholipid used in the product of the invention is a lipoid compound containing phospholipid root, and has important functions on activating cells, maintaining metabolism, basal metabolism and balanced secretion of hormones, and enhancing immunity and regenerative power of human bodies. In addition, phospholipid also has effects of promoting fat metabolism, preventing fatty liver, reducing serum cholesterol, improving blood circulation, and preventing cardiovascular diseases. In addition, phospholipid can promote gastrointestinal blood circulation and gastrointestinal peristalsis, and is helpful for preventing and improving constipation.

The invention combines the dietary fiber, the oligosaccharide and the phospholipid together, and the three play a combined role, and the combination of the dietary fiber, the oligosaccharide and the phospholipid has the effects of losing weight, treating constipation, treating diabetes, reducing hyperlipidemia, resisting aging, resisting tumors, eliminating heavy metals in vivo and the like. Especially, the kelp dietary fiber, the oligosaccharide and the phospholipid have obvious synergistic effect through respective different physiological mechanisms under the triple effects of the kelp dietary fiber, the oligosaccharide and the phospholipid, and the effects of losing weight, treating constipation, treating diabetes and reducing hyperlipidemia are very obvious.

In the invention, the kelp dietary fiber has the characteristics of loose texture, obvious net structure, more pores and uniformly distributed spatial structure, so that the kelp dietary fiber has high expansibility and high water holding capacity which are far better than those of other dietary fibers. The invention utilizes the characteristics of high expansibility and high water binding capacity of the kelp dietary fiber, and the high water binding capacity can increase the volume and speed of defecation of a human body and relieve the pressure in the rectum and the urinary system. The higher the expansive force and the water holding capacity, the higher the moisture content of the discharged excrement, and the larger and softer the excrement, so that the excrement can easily pass through the intestinal tract, and the constipation can be relieved. The oligosaccharide in the product can improve micro-ecological environment in human body, promote proliferation of Bacillus bifidus and other beneficial bacteria, reduce intestinal pH value by producing organic acid via metabolism, inhibit growth of Salmonella and putrefying bacteria in intestine, regulate gastrointestinal function, inhibit intestinal putrefying substance, change stool properties, prevent and treat constipation, increase vitamin synthesis, and improve immunity. The phospholipid in the product can promote gastrointestinal blood circulation and gastrointestinal peristalsis, and is helpful for preventing and improving constipation. The product combines the three medicines, treats constipation through different mechanisms and different aspects, so that the synergistic effect of the three medicines is very obvious.

In the invention, the kelp dietary fiber can not be digested and absorbed by gastrointestinal tracts and can not generate energy, the kelp dietary fiber can keep normal peristalsis of intestinal tracts of human bodies, and because the kelp dietary fiber has higher water-absorbing expansibility, the use of the kelp dietary fiber can generate satiety, reduce food intake, increase the volume of stomach contents, slow down the digestive emptying speed of stomach and reduce the absorption of cholesterol by organisms; the kelp dietary fiber can reduce the food intake and can also carry away redundant fat and energy from the human body; soluble dietary fiber in the kelp dietary fiber can form a film on the gastrointestinal wall, so that the absorption of glucose is prevented, and the conversion of nutrients into heat energy is prevented; in addition, the kelp dietary fiber has a porous structure, can adsorb fat and saccharides to slow down the absorption of the fat and the saccharides in the digestive tract, thereby preventing the fat and the saccharides from being excessively absorbed, and has the function of losing weight. The oligosaccharide in the product is difficult to hydrolyze by salivary enzyme and small intestine digestive enzyme, and has low calorific value and less conversion into fat; the phospholipid can decompose excessive blood lipid and cholesterol, clean blood vessel, and emulsify neutral fat and cholesterol deposited in blood vessel into harmless particles, and can be dissolved in water and discharged out of body, while preventing excessive fat from depositing on blood vessel wall and relieving pressure of heart and cerebral blood vessel wall. Therefore, the three components in the product are effective in losing weight, and the three components have different action mechanisms, so that the combined effect of losing weight of the three components is obvious. The test examples also fully demonstrate the above functions.

In the invention, the kelp dietary fiber can obviously reduce fasting blood glucose level, possibly stimulate residual beta cells to secrete insulin and improve the sensitivity of peripheral tissues to the insulin, thereby reducing the requirement on the insulin, being beneficial to the synthesis of glycogen and reducing the blood glucose level; the kelp dietary fiber in the product can remarkably inhibit the increase of postprandial blood sugar level, and may form a mucosa in stomach for the soluble kelp dietary fiber in the kelp dietary fiber, so that the digestion and absorption process of food nutrients is slowed, and the increase of blood sugar caused by exogenous glucose can be inhibited. The oligosaccharide in the product has certain effect in reducing fasting blood glucose and postprandial blood glucose. The dietary fiber and oligosaccharide have certain combined effect in reducing blood sugar of diabetes patients. The two may act in a complementary manner, with the result that the combined effect of the two should be greater than the effect of either alone.

In the invention, certain components in the dietary fiber such as gelatin can be combined with cholesterol to form gel in intestinal tracts and reduce the formation of cholesterol particles, and lignin contained in the dietary fiber can be combined with bile acid to reduce the emulsification of the bile, interfere the absorption of lipid in the intestinal tracts, reduce and slow down the absorption of the lignin to form chylomicron, so that the lipid entering the body is reduced, the cholesterol value in the body is reduced, and the cholesterol levels of very low density lipoprotein (VLDL-C) and low density lipoprotein are further influenced; the dietary fiber is combined with the cholic acid, so that the bile acid is reduced to return to the liver through the enterohepatic circulation and discharged out of the body, the cholesterol acid in the liver is reduced, the metabolism of cholesterol in the body is increased, the rate of synthesizing the cholic acid by the liver is increased, the concentration of the cholesterol in the liver is reduced, and in addition, the increase of the excretion of the cholic acid can also reduce the amount of the cholesterol in the intestinal tract which is emulsified and absorbed, so the content of the cholesterol in the body is reduced. Oligosaccharides are generally indigestible, have low sweetness and low calories, and are not easily converted to fat and cholesterol. For hyperlipidemic individuals, the main effect of oligosaccharides is to lower cholesterol levels. The oligosaccharide has effects of promoting proliferation of physiological bacteria such as Bacillus bifidus, optimizing intestinal flora, correcting intestinal flora imbalance, reducing blood sugar, and preventing increase of serum cholesterol; the phospholipid can remarkably inhibit the reduction of HDL-C. Therefore, the kelp dietary fiber, the oligosaccharide and the phospholipid have the function of reducing blood fat, the action mechanisms are different, and the blood fat reducing effect of the combined application of the kelp dietary fiber, the oligosaccharide and the phospholipid is obviously superior to that of a single component.

Obesity, hypertension, hyperlipidemia and hyperglycemia often do not appear independently, researches find that the obesity, hypertension, hyperglycemia and hyperlipidemia have a very close relation, and patients usually have four symptoms at the same time; constipation does not seem to be related to "three highs", but studies have found that people with "three highs" often have constipation, and that constipation often aggravates the symptoms of patients with "three highs". At present, the key point of treatment for hypertension, hyperlipidemia, hyperglycemia and constipation lies in diet prevention, more and more scholars and scientists consider treating the diseases and pursue breakthrough on medicines and operations, which is far less than the early prevention on diet, and once the three-high symptom is generated, the medicines can only treat the symptoms but not the root cause, and the treatment is usually performed aiming at a certain symptom, so that the comprehensive treatment effect can not be achieved, and huge side effects can be brought. The relationship between hypertension, hyperglycemia and hyperlipidemia, as well as the relationship between "three highs" and constipation, often complicates matters. According to the above-mentioned problems, the prevention of only a single meal is feared to fail to achieve the purpose of comprehensive improvement. The tablet prepared by scientifically blending dietary fiber, oligosaccharide and phospholipid of kelp has the effects of eliminating constipation, reducing obesity, reducing hypertension, reducing hyperlipidemia and reducing blood sugar. Thereby achieving the purpose of comprehensive treatment and improvement.

Detailed Description

The following examples are provided to illustrate the technical solutions for implementing the present invention, and the embodiments are not intended to limit the present invention. Equivalent substitutions or corresponding logical improvements of the present invention by those skilled in the art based on the prior knowledge belong to the scope of the present invention.

Example 1 formulation

Example 1	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.686	49.0	686.0
Xylo-oligosaccharide	0.35	25.0	350.0
				Phospholipids	0.35	25.0	350.0
Calcium stearate	0.014	1.0	14.0
				Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 200-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide and phospholipid according to the prescription amount, and uniformly mixing; c) adding a proper amount of purified water to prepare soft granules, granulating by using a 14-mesh sieve, and putting the granules into an oven with the temperature of 50-60 ℃ for drying for 1-2 hours by blowing; d) taking out, granulating with a 14-mesh sieve, adding a lubricant (calcium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 2 formulation

Example 2	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Water-soluble kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.56	40.0	560.0
				Soybean lecithin	0.4172	29.8	417.2
Magnesium stearate	0.0028	0.2	2.8
				Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the water-soluble kelp dietary fiber with a 180-mesh sieve for later use; b) weighing water-soluble kelp dietary fiber, xylo-oligosaccharide and soybean lecithin according to the prescription amount, and uniformly mixing; c) adding a proper amount of purified water to prepare soft granules, granulating by using a 16-mesh sieve, and putting the granules into a baking oven with the temperature of 50-60 ℃ for drying for 1-2 hours by blowing; d) taking out, granulating with a 16-mesh sieve, adding a lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 3 prescription

Example 3	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.98	70.0	980.0
Isomaltooligosaccharide	0.14	10.0	140.0
				Egg yolk lecithin	0.196	14.0	196.0
Leucine	0.084	6.0	84.0
				Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 150-mesh sieve for later use; b) weighing kelp dietary fiber, isomaltose hypgather and yolk lecithin according to the prescription amount, and uniformly mixing; c) adding a proper amount of purified water to prepare soft granules, granulating by using a 18-mesh sieve, and putting the granules into an oven with the temperature of 50-60 ℃ for drying for 1-2 hours by blowing; d) taking out, granulating with 18 mesh sieve, adding lubricant (leucine) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 4 prescription

Example 4	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Water-insoluble kelp dietary fiber	0.686	49.0	686.0
Galacto-oligosaccharides	0.56	40.0	560.0
				Lecithin	0.14	10.0	140.0
Sodium stearate	0.014	1.0	14.0
				Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 120-mesh sieve for later use; b) weighing the water-insoluble kelp dietary fiber, the galactooligosaccharide and the lecithin according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 20 mesh sieve, adding lubricant (sodium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 5 prescription

Example 5	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Soybean oligosaccharide	0.406	29.0	406.0
				Phospholipids	0.56	40.0	560.0
Potassium stearate	0.014	1.0	14.0
				Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, soybean oligosaccharide and phospholipid according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 30 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 30-mesh sieve, adding a lubricant (potassium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 6 prescription

Example 6	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Sodium alginate	0.462	33.0	462.0
Cottonseed oligosaccharide	0.462	33.0	462.0
				Phospholipids	0.462	33.0	462.0
Magnesium stearate	0.0084	0.6	8.4
				Silicon dioxide	0.0056	0.4	5.6
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 80-mesh sieve (sodium alginate) for later use; b) weighing sodium alginate, cottonseed oligosaccharide and phospholipid according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 30 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 30 mesh sieve, adding lubricant (magnesium stearate, silicon dioxide) according to prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 7 prescription

The process comprises the following steps: a) sieving the kelp dietary fiber with a 60-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid and a sweetening agent (aspartame) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 40-50 deg.C for 2-4 hr; d) taking out, granulating with a 20-mesh sieve, adding lubricant (sodium chloride) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 8 prescription

Example 8	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.98	70.0	980.0
Trehalose	0.2072	14.8	207.2
				Phospholipids	0.14	10.0	140.0
Xylitol, its preparation method and use	0.07	5.0	70.0
				Magnesium stearate	0.0028	0.2	2.8
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, trehalose, phospholipid and a sweetening agent (xylitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 9 prescription

Example 9	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.546	39.0	546.0
Stachyose	0.14	10.0	140.0
				Phospholipids	0.42	30.0	420.0
Sorbitol	0.28	20.0	280.0
				Glyceryl monostearate	0.014	1.0	14.0
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 120-mesh sieve for later use; b) weighing kelp dietary fiber, stachyose, phospholipid and a sweetening agent (sorbitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 60-70 deg.C for 0.5-1 h; d) taking out, granulating with a 20-mesh sieve, adding lubricant (glyceryl monostearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 10 prescription

Example 10	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.539	38.5	539.0
Fructo-oligosaccharide	0.56	40.0	560.0
				Phospholipids	0.28	20.0	280.0
Sodium cyclamate	0.007	0.5	7.0
				Sodium benzoate	0.014	1.0	14.0
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, fructooligosaccharide, phospholipid and a sweetening agent (sodium cyclamate) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with a 20-mesh sieve, adding lubricant (sodium benzoate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 11 prescription

Example 11	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.693	49.5	693.0
Arabinose oligomers	0.343	24.5	343.0
				Phospholipids	0.343	24.5	343.0
Aspartame	0.007	0.5	7.0
				Magnesium stearate	0.014	1.0	14.0
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, arabinose oligomer, phospholipid and a sweetener (aspartame) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 12 prescription

Example 12	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.7425	49.5	742.5
Oligo-coupled saccharides	0.3675	24.5	367.5
				Phospholipids	0.3675	24.5	367.5
Acesulfame potassium	0.0075	0.5	7.5
				Silicified microcrystalline cellulose	0.015	1.0	15.0
Total up to	1.5	100.0	1500.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, oligomeric coupling sugar, phospholipid and a sweetener (acesulfame potassium) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with 20 mesh sieve, adding lubricant (silicified microcrystalline cellulose) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 13 prescription

Example 13	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.495	49.5	495.0
Oligomeric aspergillus niger saccharides	0.245	24.5	245.0
				Phospholipids	0.245	24.5	245.0
Neotame	0.005	0.5	5.0
				Adipic acid	0.01	1.0	10.0
Total up to	1	100.0	1000.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, oligomeric aspergillus niger sugar, phospholipid and a sweetener (neotame) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding a lubricant (adipic acid) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 14 prescription

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, palatinose oligosaccharide, phospholipid and sweetener (saccharin sodium) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding lubricant (fumaric acid) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 15 prescription

Example 15	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.3465	49.5	346.5
Lactulose	0.1715	24.5	171.5
				Phospholipids	0.1715	24.5	171.5
Alitame	0.0035	0.5	3.5
				Palmitic acid	0.007	1.0	7.0
Total up to	0.7	100.0	700.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, lactulose, phospholipid and sweetener (alitame) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding lubricant (palmitic acid) according to the formula amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 16 prescription

Example 16	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.2475	49.5	247.5
Gentian oligosaccharide	0.1225	24.5	122.5
				Phospholipids	0.1225	24.5	122.5
Stevioside	0.0025	0.5	2.5
				Magnesium stearate	0.005	1.0	5.0
Total up to	0.5	100.0	500.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, gentiooligosaccharide, phospholipid and sweetener (stevioside) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 17 prescription

Example 17	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.4032	28.8	403.2
				Phospholipids	0.56	40.0	560.0
Lactose	0.014	1.0	14.0
				Polyethylene glycol 4000	0.0028	0.2	2.8
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid and a filler (lactose) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding a lubricant (polyethylene glycol 4000) according to the prescription amount, and totally mixing; e) tabletting: tabletting according to the specified tablet.

Example 18 prescription

Example 18	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Inulin oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.14	10.0	140.0
Mannitol	0.686	49.0	686.0
				Magnesium lauryl sulfate	0.014	1.0	14.0
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, inulin oligosaccharide, phospholipid and filler (mannitol) according to the formula amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with 20 mesh sieve, adding lubricant (magnesium lauryl sulfate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 19 prescription

Example 19	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.98	70.0	980.0
Xylo-oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.14	10.0	140.0
Microcrystalline cellulose	0.056	4.0	56.0
				Talcum powder	0.084	6.0	84.0
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid and filler (microcrystalline cellulose) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding a lubricant (talcum powder) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 20 prescription

Example 20	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.56	40.0	560.0
Xylo-oligosaccharide	0.56	40.0	560.0
				Phospholipids	0.21	15.0	210.0
Soluble starch	0.056	4.0	56.0
				Magnesium stearate	0.014	1.0	14.0
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid and a filler (soluble starch) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 21 prescription

Example 21	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.35	25.0	350.0
Xylo-oligosaccharide	0.343	24.5	343.0
				Phospholipids	0.343	24.5	343.0
Mannitol	0.35	25.0	350.0
				Magnesium stearate	0.014	1.0	14.0
Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid and a filler (mannitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 22 prescription

Example 22	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.6	30.0	600.0
Xylo-oligosaccharide	0.2	10.0	200.0
				Phospholipids	0.2	10.0	200.0
Sorbitol	0.98	49.0	980.0
				Magnesium stearate	0.02	1.0	20.0
Total up to	2	100.0	2000.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid and a filler (sorbitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 23 prescription

Example 23	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.56	40.0	560.0
				Soybean lecithin	0.3752	26.8	375.2
Silicon dioxide	0.042	3.0	42.0
				Magnesium stearate	0.0014	0.1	1.4
Aspartame	0.0014	0.1	1.4
				Total up to	1.4	100.0	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, soybean phospholipid and a sweetening agent (aspartame) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 24 prescription

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, soybean phospholipid and a sweetening agent (aspartame) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 20 mesh sieve, adding lubricant (magnesium stearate, silicon dioxide) according to prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 25 prescription

Example 25	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.84	60.0	840.0
Xylo-oligosaccharide	0.392	28.0	392.0
				Soybean lecithin	0.14	10.0	140.0
Silicon dioxide	0.007	0.5	7.0
				Magnesium stearate	0.014	1.0	14.0
Aspartame	0.007	0.5	7.0
				Total up to	1.4	100	1400.0

Example 26 prescription

Example 26	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.462	33.0	462.0
Xylo-oligosaccharide	0.35	25.0	350.0
				Soybean lecithin	0.56	40.0	560.0
Silicon dioxide	0.007	0.5	7.0
				Magnesium stearate	0.014	1.0	14.0
Aspartame	0.007	0.5	7.0
				Total up to	1.4	100	1400.0

Example 27 prescription

Example 27	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.6615	49.0	661.50
Xylo-oligosaccharide	0.33075	24.5	330.75
				Soybean lecithin	0.33075	24.5	330.75
Silicon dioxide	0.00675	0.5	6.75
				Magnesium stearate	0.0135	1.0	13.50
Aspartame	0.00675	0.5	6.75
				Total up to	1.35	100	1350.00

Example 28 prescription

Example 28	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.56	40.0	560.0
				Phospholipids	0.14	10.0	140.0
Maltitol	0.1946	13.9	194.6
				Polyethylene glycol 6000	0.084	6.0	84.0
Aspartame	0.0014	0.1	1.4
				Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetening agent (aspartame) and a filling agent (maltitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 20 mesh sieve, adding lubricant (polyethylene glycol 6000) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 29 prescription

Example 29	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.98	70.0	980.0
Xylo-oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.14	10.0	140.0
Dextrin	0.1302	9.3	130.2
				Magnesium stearate	0.0028	0.2	2.8
Aspartame	0.007	0.5	7.0
				Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetening agent (aspartame) and a filling agent (dextrin) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding a lubricating (magnesium stearate) agent according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 30 prescription

Example 30	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.56	40.0	560.0
Starch	0.014	1.0	14.0
				Stearic acid	0.014	1.0	14.0
Glucose	0.252	18.0	252.0
				Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetening agent (glucose) and a filling agent (starch) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (stearic acid) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 31 prescription

Example 31	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.14	10.0	140.0
Isomaltooligosaccharides	0.686	49.0	686.0
				Magnesium stearate	0.007	0.5	7.0
Fructose	0.007	0.5	7.0
				Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetener (fructose) and a filler (isomalto-oligosaccharide) according to the formula amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 32 prescription

Example 32	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.462	33.0	462.0
Xylo-oligosaccharide	0.161	11.5	161.0
				Phospholipids	0.14	10.0	140.0
Pregelatinized starch	0.35	25.0	350.0
				Magnesium stearate	0.007	0.5	7.0
Xylitol, its preparation method and use	0.28	20.0	280.0
				Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, sweetener (xylitol) and filler (pregelatinized starch) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant (magnesium stearate) according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 33 prescription

Example 33	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.56	40.0	560.0
				Phospholipids	0.14	10.0	140.0
Mannitol	0.2352	16.8	235.2
				Silicon dioxide	0.0014	0.1	1.4
Magnesium stearate	0.042	3.0	42.0
				Xylitol, its preparation method and use	0.0014	0.1	1.4
Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetening agent (xylitol) and a filling agent (mannitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 20 mesh sieve, adding lubricant (magnesium stearate, silicon dioxide) according to prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 34 prescription

Example 34	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.98	70.0	980.0
Xylo-oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.14	10.0	140.0
Mannitol	0.014	1.0	14.0
				Silicon dioxide	0.042	3.0	42.0
Magnesium stearate	0.0014	0.1	1.4
				Xylitol, its preparation method and use	0.0826	5.9	82.6
Total up to	1.4	100	1400.0

Example 35 prescription

Example 35	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.56	40.0	560.0
Starch	0.07	5.0	70.0
				Silicon dioxide	0.007	0.5	7.0
Magnesium stearate	0.014	1.0	14.0
				Xylitol, its preparation method and use	0.189	13.5	189.0
Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetening agent (xylitol) and a filling agent (starch) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, granulating with a 20-mesh sieve, adding the lubricant according to the prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 36 prescription

Example 36	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.483	34.5	483.0
Xylo-oligosaccharide	0.238	17.0	238.0
				Phospholipids	0.238	17.0	238.0
Mannitol	0.14	10.0	140.0
				Silicon dioxide	0.007	0.5	7.0
Magnesium stearate	0.014	1.0	14.0
				Maltose	0.28	20.0	280.0
Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetening agent (maltose) and a filling agent (mannitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 20 mesh sieve, adding lubricant (magnesium stearate, silicon dioxide) according to prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 37 prescription

Example 37	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.42	30.0	420.0
Xylo-oligosaccharide	0.14	10.0	140.0
				Phospholipids	0.14	10.0	140.0
Mannitol	0.686	49.0	686.0
				Silicon dioxide	0.0028	0.2	2.8
Magnesium stearate	0.0084	0.6	8.4
				Sucralose	0.0028	0.2	2.8
Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, sweetener (sucralose) and filler (mannitol) according to the formula amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 20 mesh sieve, adding lubricant (magnesium stearate, silicon dioxide) according to prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 38 prescription

Example 38	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.63	45.0	630.0
Xylo-oligosaccharide	0.28	20.0	280.0
				Phospholipids	0.28	20.0	280.0
Mannitol	0.182	13.0	182.0
				Silicon dioxide	0.007	0.5	7.0
Magnesium stearate	0.014	1.0	14.0
				Aspartame	0.007	0.5	7.0
Total up to	1.4	100	1400.0

The process comprises the following steps: a) sieving the kelp dietary fiber with a 100-mesh sieve for later use; b) weighing kelp dietary fiber, xylo-oligosaccharide, phospholipid, a sweetening agent (aspartame) and a filling agent (mannitol) according to the prescription amount, and uniformly mixing; c) adding purified water to make into soft granules, granulating with 20 mesh sieve, and drying in oven at 50-60 deg.C for 1-2 hr; d) taking out, sieving with 20 mesh sieve, adding lubricant (magnesium stearate, silicon dioxide) according to prescription amount, and mixing; e) tabletting: tabletting according to the specified tablet.

Example 39 prescription

Example 39	Dosage of each tablet g	Amount per tablet (%)	1000 tablets (g)
				Kelp dietary fiber	0.66	33.0	660.0
Xylo-oligosaccharide	0.33	16.5	330.0
				Phospholipids	0.33	16.5	330.0
Mannitol	0.64	32.0	640.0
				Silicon dioxide	0.01	0.5	10.0
Magnesium stearate	0.02	1.0	20.0
				Aspartame	0.01	0.5	10.0
Total up to	2	100	2000.0

Example 40

The tablets of example 27 were coated with a gastric film to prepare film-coated tablets.

EXAMPLE 41

The tablets of example 27 were coated with an enteric film coating to prepare film-coated tablets.

Example 42

Tablets of example 27 were enteric coated to make sugar-coated tablets.

Test example 1: basic parameters of tablets prepared in each example

Appearance property: an observation method is adopted.

Weight difference: the test was carried out according to the weight difference method under the item of 0101 tablets in the four parts of pharmacopoeia of the people's republic of China 2015 edition.

Hardness: hardness was measured with a YPD-200C type tablet hardness tester, Shanghai yellow sea medical testing Instrument Co.

Friability: the tablets were examined according to the friability test method of the four 0923 tablets in pharmacopoeia 2015 edition of the people's republic of China.

The mouthfeel is as follows: please 10 people to taste respectively, and gargle after the taste is finished according to the scores (0-10 points, the taste is worst 0 point, and the taste is best 10 points), and taste of the next prescription after 30 minutes. The average of 10 persons was taken as the final taste index. The results of the measurement of the basic parameters of the tablets produced in each example are shown in Table 1.

Test example 2:

840 constipation sufferers are divided into 42 groups, 20 patients are respectively taken with tablets of each embodiment of the product, wherein, 3 tablets are taken at a time for example 16, 2 tablets are taken at a time for examples 14, 15, 31, 32 and 37, 1 tablet is taken at a time for other embodiments, 3 times a day and 2 weeks are taken continuously, and the times of defecating and defecation are recorded every day during the taking period.

The judgment standard of the curative effect is as follows: the method has the following advantages: clinical symptoms disappear, and stools are stable for half a month after 1 time per day; secondly, the method is effective: the clinical symptoms basically disappear or obviously improve, and the stool is basically normal or the times are obviously increased; ③ invalid: no significant improvement in symptoms or stool frequency. The constipation after taking the product of each embodiment is shown in table 2.

Test example 3:

840 obese patients were divided into 42 groups, and 20 patients were each administered the tablets of each example of the product, wherein example 16 was administered 3 tablets each time, examples 14, 15, 31, 32, and 37 were administered 2 tablets each time, and other examples were administered 1 tablet each time, 3 times daily, continuously for 4 weeks, weighed before and after 4 weeks of treatment, and counted for the number of people with weight loss of 20kg or more, 10kg to 20kg to total body weight loss, and 5kg to less than 5kg to total body weight loss. The weight loss after administration of each product is shown in Table 3.

Test example 4:

210 diabetic patients were divided into 42 groups, and 5 patients were administered with tablets of each example of the product, wherein 3 tablets were administered at a time in example 16, 2 tablets were administered at a time in examples 14, 15, 31, 32, and 37, and 1 tablet was administered at a time in other examples, 3 times daily, and 3 months were continuously administered, and fasting blood glucose and glycated hemoglobin were measured before and 3 months after administration, respectively. Then, the average values of 5 persons' fasting blood sugar and glycosylated hemoglobin are taken.

The change of the mean values of fasting plasma glucose and glycated hemoglobin before and after administration of the products of each example is shown in Table 4.

Test example 5:

210 patients with hyperlipidemia were divided into 42 groups, and 5 patients in each group were administered with the tablets of each example of the product, wherein example 16 was administered 3 tablets each time, examples 14, 15, 31, 32, and 37 were administered 2 tablets each time, and other examples were administered 1 tablet each time, 3 times daily, continuously for 4 weeks, and blood lipid test was performed before and 4 weeks after treatment. Then, the average value of the blood lipids of 5 persons was taken. The mean blood lipid changes before and after administration of the products of each example are shown in Table 5.

Test example 6:

840 patients with hypertension were divided into 42 groups of 20, and each group was administered with tablets of each example of the product, wherein example 16 was administered 3 tablets each time, examples 14, 15, 31, 32, 37 were administered 2 tablets each time, and other examples were administered 1 tablet each time, 3 times daily for 4 weeks, and blood pressure was measured before and after 4 weeks of treatment. Then, the average of 20 blood pressures was taken. The blood pressure changes before and after taking the products of each example are shown in Table 6.

Test example 7:

in each of examples 1 to 5, the patients were asked about the flavor and taste after taking them by random visits and group statistics, and all of the patients showed no bad flavor, easy administration and good taste.

TABLE 1 basic parameters of tablets prepared in the examples

TABLE 2 treatment of constipation after administration of the products of the examples

	Obvious effect (example)	Effective (example)	Invalid (example)	Total (example)
					Example 1	14	6	0	20
Example 2	12	7	1	20
					Example 3	8	10	2	20
Example 4	11	8	1	20
					Example 5	8	10	2	20
Example 6	9	9	2	20
					Example 7	12	8	0	20
Example 8	10	9	1	20
					Example 9	9	10	1	20
Example 10	10	10	0	20
					Example 11	12	7	1	20
Example 12	11	9	0	20
					Example 13	8	10	2	20
Example 14	10	9	1	20
					Example 15	12	7	1	20
Example 16	11	8	1	20
					Example 17	11	7	2	20
Example 18	11	8	1	20
					Example 19	11	8	1	20
Example 20	11	8	1	20
					Example 21	14	6	0	20
Example 22	11	7	2	20
					Example 23	10	9	1	20
Example 24	11	8	1	20
					Example 25	14	6	0	20
Example 26	14	6	0	20
					Example 27	12	8	0	20
Example 28	13	6	1	20
					Example 29	9	9	2	20
Example 30	11	8	1	20
					Example 31	11	8	1	20
Example 32	13	7	0	20
					Example 33	12	8	0	20
Example 34	12	7	1	20
					Example 35	12	6	2	20
Example 36	10	8	2	20
					Example 37	10	9	1	20
Example 38	12	6	2	20
					Example 39	10	10	0	20
Example 40	9	9	2	20
					EXAMPLE 41	9	9	2	20
Example 42	12	7	1	20

TABLE 3 statistical table of weight loss of postpartum products after administration

4 mean change of fasting plasma glucose and glycated hemoglobin before and after taking the products of each example

TABLE 5 mean blood lipid changes before and after administration of the products of the examples

TABLE 6 mean blood pressure Change before and after administration of the products of the examples

Claims

1. The application of phospholipid in reducing the friability of the kelp dietary fiber tablet comprises the active ingredients of kelp dietary fiber, oligosaccharide and phospholipid, and the auxiliary materials are pharmaceutically acceptable auxiliary materials for preparing the tablet, and the auxiliary materials at least comprise a lubricant, and are characterized in that the dosage of each ingredient is 30-70 parts by mass of kelp dietary fiber, 10-40 parts by mass of oligosaccharide, 10-40 parts by mass of phospholipid, and 0.2-6 parts by mass of the lubricant in the auxiliary materials.

2. The application of phospholipid in improving the mouthfeel of the kelp dietary fiber tablet comprises active ingredients of kelp dietary fiber, oligosaccharide and phospholipid, and auxiliary materials are pharmaceutically acceptable auxiliary materials for preparing the tablet, and the auxiliary materials at least comprise a lubricant, and is characterized in that the active ingredients comprise, by mass, 30-70 parts of kelp dietary fiber, 10-40 parts of oligosaccharide, 10-40 parts of phospholipid, and 0.2-6 parts of lubricant in the auxiliary materials.

3. The use according to claim 1 or 2, characterized in that the kelp dietary fiber in the kelp dietary fiber sheet is selected from one of water-soluble kelp dietary fiber, water-insoluble kelp dietary fiber or a mixture thereof.

4. The use according to claim 1 or 2, wherein the kelp dietary fiber in the kelp dietary fiber sheet is sodium alginate.

5. The use according to claim 1 or 2, characterized in that the oligosaccharide in the kelp dietary fiber tablet is selected from one or more of xylooligosaccharide, isomaltooligosaccharide, fructooligosaccharide, galactooligosaccharide, soybean oligosaccharide, cottonseed oligosaccharide, inulin oligosaccharide, gentiooligosaccharide, palatinose oligosaccharide, aspergillus niger oligosaccharide, coupling oligosaccharide, arabinose oligosaccharide, lactulose, trehalose, stachyose, chitosan and chitosan.

6. Use according to claim 5, characterized in that the oligosaccharides are selected from xylo-oligosaccharides.

7. The use according to claim 1 or 2, wherein the phospholipid in the kelp dietary fiber sheet is selected from one of plant-derived phospholipids, animal-derived phospholipids or a mixture thereof, or single-component phospholipids obtained by separating and purifying plant-derived phospholipids and animal-derived phospholipids; wherein the plant-derived phospholipid is phospholipid derived from semen glycines, semen gossypii, semen Brassicae campestris, semen Arachidis Hypogaeae, semen Helianthi, etc.; wherein the animal-derived phospholipid is prepared from animal egg, brain, liver, kidney, heart, lung, etc.; wherein the separated and purified single-component phospholipid is selected from lecithin, cephalin, inositol phospholipid, serine phospholipid, phosphatidyl glycerol, diphosphatidyl glycerol, plasmalogen, lysophospholipid, sphingomyelin, and sphingoglycolipid.

8. Use according to claim 7, characterized in that said phospholipid of vegetable origin is soybean phospholipid and said phospholipid of animal origin is egg yolk lecithin.

9. The use according to claim 1 or 2, characterized in that the kelp dietary fiber tablet formulation is a chewable tablet in which the kelp dietary fiber used is a mixture of water-soluble kelp dietary fiber and water-insoluble kelp dietary fiber; the oligosaccharide is xylo-oligosaccharide; the phospholipid is soybean phospholipid; the auxiliary materials comprise a lubricant consisting of magnesium stearate and silicon dioxide; the components are 30-70 parts of kelp dietary fiber, 10-40 parts of xylo-oligosaccharide, 10-40 parts of soybean phospholipid, 0.1-3 parts of silicon dioxide and 0.1-3 parts of magnesium stearate.

10. The use according to claim 1 or 2, characterized in that the kelp dietary fiber tablet adjuvant further comprises a sweetener, the sweetener is selected from aspartame, the phospholipid is selected from soybean phospholipid, the oligosaccharide is selected from xylo-oligosaccharide, and the dosage of each component is kelp dietary fiber 49, xylo-oligosaccharide 24.5, soybean phospholipid 24.5, silicon dioxide 0.5, magnesium stearate 1 and aspartame 0.5 in parts by mass.